We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

127 hedge funds and large institutions have $88.4M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

56% more call options, than puts

Call options by funds: $1.95M | Put options by funds: $1.25M

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

12% more funds holding

Funds holding: 113 → 127 (+14)

1.29% more ownership

Funds ownership: 29.8% → 31.09% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

26% less capital invested

Capital invested by funds: $119M → $88.4M (-$30.7M)

Holders
127
Holders Change
+14
Holders Change %
+12.39%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
45
Reduced
33
Closed
5
Calls
$1.95M
Puts
$1.25M
Net Calls
+$696K
Net Calls Change
-$1.48M

Top Buyers

1
TSC
Two Seas Capital
New York
+$5.07M
2
OMC
Oasis Management Company
Cayman Islands
+$2.42M
3
Marshall Wace
Marshall Wace
United Kingdom
+$925K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$691K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$529K

Top Sellers

1
BC
Brookfield Corp
Ontario, Canada
-$5.19M
2
Millennium Management
Millennium Management
New York
-$1.53M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$533K
4
Simplex Trading
Simplex Trading
Illinois
-$209K
5
Goldman Sachs
Goldman Sachs
New York
-$189K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$14.3M -$171K -72,564 -1%
TSC
2
Two Seas Capital
New York
$10.8M +$5.07M +2,152,041 +61%
Vanguard Group
3
Vanguard Group
Pennsylvania
$10.1M +$152K +64,485 +1%
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$9.48M +$691K +293,668 +6%
Millennium Management
5
Millennium Management
New York
$6.7M -$1.53M -648,876 -16%
State Street
6
State Street
Massachusetts
$3.84M +$123K +52,456 +3%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$3.84M +$529K +224,798 +13%
FCM
8
FourWorld Capital Management
New York
$3.82M +$469K +199,090 +11%
Assenagon Asset Management
9
Assenagon Asset Management
Luxembourg
$3.62M -$533K -226,245 -11%
Osaic Holdings
10
Osaic Holdings
Arizona
$2.61M – – –
OMC
11
Oasis Management Company
Cayman Islands
$1.96M +$2.42M +1,026,672 New
Northern Trust
12
Northern Trust
Illinois
$1.72M +$8.42K +3,575 +0.4%
BFM
13
Boothbay Fund Management
New York
$1.47M +$506K +215,132 +39%
Goldman Sachs
14
Goldman Sachs
New York
$1.24M -$189K -80,129 -11%
Wellington Management Group
15
Wellington Management Group
Massachusetts
$828K -$169K -71,700 -14%
Primecap Management
16
Primecap Management
California
$809K – – –
Marshall Wace
17
Marshall Wace
United Kingdom
$751K +$925K +392,932 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$736K +$72.1K +30,612 +9%
N
19
Nuveen
North Carolina
$623K -$2.79K -1,185 -0.4%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$553K +$9.74K +4,137 +1%
Charles Schwab
21
Charles Schwab
California
$549K -$1.26K -535 -0.2%
DekaBank Deutsche Girozentrale
22
DekaBank Deutsche Girozentrale
Germany
$485K – – –
JAMONY
23
Jacob Asset Management of New York
California
$420K – – –
Morgan Stanley
24
Morgan Stanley
New York
$405K -$16.4K -6,948 -3%
Parallax Volatility Advisers
25
Parallax Volatility Advisers
California
$383K +$414 +176 +0.1%
1
2 3 4 5

ABUS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2022, worth a combined $88.4M — down 26% from $119M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ABUS positions and 5 closed out — a net gain of 15 holders — while 45 added to existing stakes and 33 trimmed.

The largest buyer was Two Seas Capital, adding an estimated $5.07M. The largest seller was Brookfield Corp, exiting entirely with an estimated $5.19M sold.

  • 127 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $88.4M of Arbutus Biopharma stock for Q3 2022, down 26% quarter-over-quarter.
  • 20 funds opened new Arbutus Biopharma positions in Q3 2022 and 5 closed out, a net change of +15 holders.
  • The largest Arbutus Biopharma buyer in Q3 2022 was Two Seas Capital, an estimated $5.07M added.
  • The largest Arbutus Biopharma seller in Q3 2022 was Brookfield Corp, an estimated $5.19M sold.

Based on aggregated 13F filings for Q3 2022.